By Corey Mann Novocure stock is on the rise due to the acceleration of the company’s lung cancer treatment trial. In fact, an independent data monitoring committee (DMC) has high hopes for Novocure (Nasdaq: NVCR) and its breakthrough research for stage 4 non-small cell lung cancer.
Novocure Stock History and Background
Novocure was founded in 2000 by Professor Yoram Palti. And its mission is to treat and destroy cancer tumor cells while “sparing healthy tissue and avoiding many of the life-altering side effects of existing cancer therapies.”
In 2015, the innovative tumor treatment company went public on the Nasdaq. The initial public offering (IPO) came in …read more
